Abstract
Chemotherapy resistance remains a major clinical problem in patients with B-cell chronic lymphocytic leukemia (B-CLL). Proteasome inhibitors are able to induce apoptosis in chemotherapy-resistant B-CLL cells in vitro. Exposure of B-CLL cells to the proteasome inhibitors, MG132 and lactacystin, resulted in inhibition of proteasomal activity within 30 min of treatment and was accompanied by an increase in the level of ubiquitinated proteins. Proteasome inhibitors did not alter the levels of expression of the proapoptotic Bcl-2 family proteins, Bax and Bid, prior to the onset of apoptosis. Instead, proteasome inhibitors induced a caspase-independent conformational change in Bax (as shown by a conformation-specific Bax antibody) and its translocation to mitochondria, resulting in mitochondrial perturbation, as evidenced by loss of the mitochondrial membrane potential and cytochrome c release. Similar conformational change and subcellular localization of Bax were observed during apoptosis induced with fludarabine, chlorambucil and prednisolone. These data suggest that alteration of Bax conformation and its redistribution to mitochondria are common and early features of B-CLL apoptosis in response to proteasome inhibitors and other chemotherapeutic agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams J . (2002). Curr. Opin. Chem. Biol., 6, 493–500.
Adams J and Elliott PJ . (2000). Oncogene, 19, 6687–6692.
Almond JB and Cohen GM . (2002). Leukemia, 16, 433–443.
Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain K and Cohen GM . (2001). Leukemia, 15, 1388–1397.
An B, Goldfarb RH, Siman R and Dou QP . (1998). Cell Death Differ., 5, 1062–1075.
Antonsson B, Montessuit S, Sanchez B and Martinou JC . (2001). J. Biol. Chem., 276, 11615–11623.
Bannerji R and Byrd JC . (2000). Curr. Opin. Oncol., 12, 22–29.
Barragan M, Bellosillo B, Campas C, Colomer D, Pons G and Gil J . (2002). Blood, 99, 2969–2976.
Baumeister W, Walz J, Zuhl F and Seemuller E . (1998). Cell, 92, 367–380.
Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dorken B and Daniel PT . (2002). Leukemia, 16, 1035–1044.
Bratton SB, Walker G, Srinivasula SM, Sun XM, Butterworth M, Alnemri ES and Cohen GM . (2001). EMBO J., 20, 998–1009.
Breitschopf K, Zeiher AM and Dimmeler S . (2000). J. Biol. Chem., 275, 21648–21652.
Cain K, Brown DG, Langlais C and Cohen GM . (1999). J. Biol. Chem., 274, 22686–22692.
Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M and McConkey DJ . (1998). Blood, 92, 4220–4229.
Chang YC, Lee YS, Tejima T, Tanaka K, Omura S, Heintz NH, Mitsui Y and Magae J . (1998). Cell Growth Differ., 9, 79–84.
Ciechanover A . (1994). Cell, 79, 13–21.
Cohen GM . (1997). Biochem. J., 326, 1–16.
Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL and Magdelenat H . (1998). Br. J. Cancer, 77, 1103–1107.
Deng Y, Lin Y and Wu X . (2002). Genes Dev., 16, 33–45.
Dewson G, Cohen GM and Wardlaw AJ . (2001). Blood, 98, 2239–2247.
Dou QP and Li B . (1999). Drug Resist. Update, 2, 215–223.
Drexler HC . (1997). Proc. Natl. Acad. Sci. USA, 94, 855–860.
Earnshaw WC, Martins LM and Kaufmann SH . (1999). Annu. Rev. Biochem., 68, 383–424.
Eskes R, Antonsson B, Osen-Sand A, Montessuit S, Richter C, Sadoul R, Mazzei G, Nichols A and Martinou JC . (1998). J. Cell Biol., 143, 217–224.
Ghatan S, Larner S, Kinoshita Y, Hetman M, Patel L, Xia Z, Youle RJ and Morrison RS . (2000). J. Cell Biol., 150, 335–347.
Gilmore AP, Metcalfe AD, Romer LH and Streuli CH . (2000). J. Cell Biol., 149, 431–446.
Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ and Shore GC . (1998). J. Cell Biol., 143, 207–215.
Gross A, Jockel J, Wei MC and Korsmeyer SJ . (1998). EMBO J., 17, 3878–3885.
Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC . (2001). Cancer Res., 61, 3071–3076.
Hsu YT, Wolter KG and Youle RJ . (1997). Proc. Natl. Acad. Sci. USA, 94, 3668–3672.
Hsu YT and Youle RJ . (1997). J. Biol. Chem., 272, 13829–13834.
Hsu YT and Youle RJ . (1998). J. Biol. Chem., 273, 10777–10783.
Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D and Reed JC . (1998). Proc. Natl. Acad. Sci. USA, 95, 4997–5002.
Kalil N and Cheson BD . (1999). Oncologist, 4, 352–369.
Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata JM, Wang HG, Shabaik A, Tudor G, Krajewski S, Myers TG, Johnson GS, Sausville EA and Reed JC . (1998). Am. J. Pathol., 152, 51–61.
Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD . (1997). Science, 275, 1132–1136.
Li B and Dou QP . (2000). Proc. Natl. Acad. Sci. USA, 97, 3850–3855.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X . (1997). Cell, 91, 479–489.
Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, Frauwirth K, Chen Y, Wei M, Eng VM, Adelman DM, Simon MC, Ma A, Golden JA, Evan G, Korsmeyer SJ, MacGregor GR and Thompson CB . (2000). Mol. Cell, 6, 1389–1399.
Lopes UG, Erhardt P, Yao R and Cooper GM . (1997). J. Biol. Chem., 272, 12893–12896.
MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM and Alnemri ES . (1997). J. Biol. Chem., 272, 25417–25420.
MacFarlane M, Cohen GM and Dickens M . (2000). Biochem. J., 348, 93–101.
MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH and Cohen GM . (2002). Oncogene, 21, 6809–6818.
Maianski NA, Mul FP, van Buul JD, Roos D and Kuijpers TW . (2002). Blood, 99, 672–679.
Makin GW, Corfe BM, Griffiths GJ, Thistlethwaite A, Hickman JA and Dive C . (2001). EMBO J., 20, 6306–6315.
Marshansky V, Wang X, Bertrand R, Luo H, Duguid W, Chinnadurai G, Kanaan N, Vu MD and Wu J . (2001). J. Immunol., 166, 3130–3142.
Martinou JC and Green DR . (2001). Nat. Rev. Mol. Cell Biol., 2, 63–67.
Marzo I, Brenner C, Zamzami N, Jurgensmeier JM, Susin SA, Vieira HL, Prevost MC, Xie Z, Matsuyama S, Reed JC and Kroemer G . (1998). Science, 281, 2027–2031.
McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC and Keating M . (1996). J. Immunol., 156, 2624–2630.
Meriin AB, Gabai VL, Yaglom J, Shifrin VI and Sherman MY . (1998). J. Biol. Chem., 273, 6373–6379.
Murray RZ and Norbury C . (2000). Anticancer Drugs, 11, 407–417.
Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S and Possinger K . (2000). Eur. J. Haematol., 65, 221–236.
Nechushtan A, Smith CL, Hsu YT and Youle RJ . (1999). EMBO J., 18, 2330–2341.
Orlowski RZ . (1999) Cell Death Differ., 6, 303–313.
Penault-Llorca F, Bouabdallah R, Devilard E, Charton-Bain MC, Hassoun J, Birg F and Xerri L . (1998). Pathol. Res. Pract., 194, 457–464.
Pepper C, Hoy T and Bentley P . (1998). Leukemia Lymphoma, 28, 355–361.
Pepper C, Thomas A, Hoy T and Bentley P . (1999). Br. J. Haematol., 104, 581–588.
Putcha GV, Deshmukh M and Johnson Jr EM . (1999). J. Neurosci., 19, 7476–7485.
Reed JC . (1998). Semin. Hematol., 35, 3–13.
Rossé T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B and Borner C . (1998). Nature, 391, 496–499.
Scaduto Jr RC and Grotyohann LW . (1999). Biophys. J., 76, 469–477.
Shimizu S, Narita M and Tsujimoto Y . (1999). Nature, 399, 483–487.
Shinohara K, Tomioka M, Nakano H, Tone S, Ito H and Kawashima S . (1996). Biochem. J., 317, 385–388.
Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR and Cohen GM . (1999). J. Biol. Chem., 274, 5053–5060.
Suzuki M, Youle RJ and Tjandra N . (2000). Cell, 103, 645–654.
Tsubuki S, Saito Y, Tomioka M, Ito H and Kawashima S . (1996) J. Biochem. (Tokyo), 119, 572–576.
Tsuruta F, Masuyama N and Gotoh Y . (2002). J. Biol. Chem., 277, 14040–14047.
Van Loo G, Saelens X, Van Gurp M, MacFarlane M, Martin SJ and Vandenabeele P . (2002). Cell Death Differ., 9, 1031–1042.
Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ . (2001). Science, 292, 727–730.
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ . (1997). J. Cell Biol., 139, 1281–1292.
Yamaguchi H and Wang HG . (2001). Oncogene, 20, 7779–7786.
Acknowledgements
We thank Dr Marion MacFarlane, Dr Shawn Bratton, and Prof. Pierluigi Nicotera for their advice and critique of the manuscript. We thank Kul Sikand for his invaluable assistance with the confocal analysis. This work was supported in part by the Medical Research Council and a grant from the European Union (Grant # QLG1-1999-00739).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dewson, G., Snowden, R., Almond, J. et al. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene 22, 2643–2654 (2003). https://doi.org/10.1038/sj.onc.1206326
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206326
Keywords
This article is cited by
-
Mitochondrial E3 ubiquitin ligase MARCHF5 controls BAK apoptotic activity independently of BH3-only proteins
Cell Death & Differentiation (2023)
-
BAX mitochondrial integration is regulated allosterically by its α1−α2 loop
Cell Death & Differentiation (2021)
-
RETRACTED ARTICLE: Jacarelhyperol A induced apoptosis in leukaemia cancer cell through inhibition the activity of Bcl-2 proteins
BMC Cancer (2014)
-
Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells
Cell Death & Differentiation (2010)
-
Compound K, a metabolite of ginseng saponin, induces apoptosis via caspase-8-dependent pathway in HL-60 human leukemia cells
BMC Cancer (2009)